Profil bibliographique

Ewa Lech‐Marańda

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

354Publications signalées

7809Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Publications récentes

2026 articleOpenAlex

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia – real-world analysis of Polish adult leukemia study group

Anita Soboń, Elżbieta Iskierka‐Jazdzewska, Joanna Drozd‐Sokołowska, Anna Puła et autres

0 citationsLeukemia & lymphoma/Leukemia and lymphoma

Accès ouvert 2026 articleOpenAlex

Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy – a multicenter study from Polish Adult Leukemia Group

Bożena Katarzyna Budziszewska, Michał Łomiak, Joanna Barankiewicz, Elżbieta Patkowska et autres

0 citationsAnnals of Hematology

Accès ouvert 2025 articleOpenAlex

Exclusion of patients with renal impairment from phase 3 randomized controlled trials in hematologic malignancies

Danuta Kłosowska, Michał Ordak, Ewa Lech‐Marańda, Leszek Pączek et autres

0 citationsInternational Journal of Cancer

2025 conference-abstractOpenAlex

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Chan Y. Cheah, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak et autres

4 citationsBlood

2025 conference-abstractOpenAlex

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Agnieszka Wierzbowska, Anna Czyż, Agnieszka Pluta, Marta Libura et autres

1 citationBlood

Accès ouvert 2025 conference-abstractOpenAlex

Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocol

Sebastian Giebel, Elżbieta Patkowska, Anna Kopińska, Anna Szmigielska‐Kapłon et autres

0 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Agnieszka Wierzbowska, Agnieszka Pluta, Anna Czyż, Marta Libura et autres

0 citationsBlood

Accès ouvert 2025 articleOpenAlex

Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial

Giovanni Martinelli, Scott R. Solomon, Sudipto Mukherjee, Armando Santoro et autres

2 citationsBlood Neoplasia

Accès ouvert 2025 articleOpenAlex

Advances in the diagnosis and treatment of marginal zone lymphomas

Ewa Lech‐Marańda

0 citationsActa Haematologica Polonica

Accès ouvert 2025 articleOpenAlex

Anticoagulant therapy in patients with cancer and thrombocytopenia

Sebastian Szmit, Jarosław Kępski, Ewa Lech‐Marańda, Dariusz M. Kowalski et autres

7 citationsJournal of Thrombosis and Thrombolysis

Accès ouvert 2025 articleOpenAlex

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study

Nirav N. Shah, Pier Luigi Zinzani, Michael Wang, Sunita D. Nasta et autres

5 citationsBlood Advances

2025 articleOpenAlex

Characteristics of symptomatic cardiovascular events in a 3-year single-center cardio-onco-hematology program in Poland (Cardio-Hemato-Oncology Programe CHOP-3Y)

Jarosław Kępski, Sebastian Szmit, Ewa Lech‐Marańda

0 citationsEuropean Heart Journal Supplements

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.